NRG-BN003

Open to Accrual

Return to Protocol Table

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Principal Investigator

Leland Rogers, MD FACRO

Status

Open to Accrual

Date Opened To Accrual

June 14 2017

Disease Site

Brain [BN]

Benign Brain Tumors

Phase

III

Developmental Therapeutics

Primary Objective

The primary endpoint is progression-free survival (PFS). The principle objective is to determine the extent of clinical benefit of the addition of adjuvant radiotherapy (RT) to gross total resection (GTR) for patients with newly diagnosed World Health Organization (WHO) grade II meningioma.

Patient Population

Newly diagnosed gross totally resected (Simpson Grade 1-3) WHO grade II meningioma

Target Accrual

163

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.

Patient Study Webpage

To learn more about this study, visit the Patient Study Webpage.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.